# AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

> **NCT07094113** · PHASE1 · RECRUITING · sponsor: **Amgen** · enrollment: 434 (estimated)

## Conditions studied

- KRAS Altered Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** AMG 410
- **DRUG:** Pembrolizumab
- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT07094113
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-31
- **Primary completion:** 2028-04-18
- **Final completion:** 2031-04-20
- **Target enrollment:** 434 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07094113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07094113, "AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07094113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*